In patients with Guillain-Barré syndrome, tanruprubart yielded significant improvements in muscle strength, with patients ...
First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from ...
First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from ...
SE’s $2.2B Forte Biosciences, Inc. deal adds FB-102 to expand pipeline, but valuation & Vyvgart patent risks raise caution.
Ciprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for patients requiring ...
Scientists have advanced the field of cancer treatment by leveraging the body’s immune system to recognize and target tumors.
Ciprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for patients requiring ...
One-day summit on Ayur-oncology to be held at Government Ayurveda College in Thiruvananthapuram on Aug 11: Peethaambaran Kunnathoor, Chennai ...
Disclosure: Conran has received grants from the Sao Paulo Research Foundation and Novartis AG; and participated in data safety monitoring or advisory boards for Novo Nordisk. Rees has participated on ...
The complement system is an important part of the humoral immune defence in mammals that is formed by about 35 soluble and cell-surface proteins. Together these proteins enable the host to recognize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results